{"organizations": [], "uuid": "dbed060f4b8ba451279ce5e28669f4ec816ee853", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180110.html", "section_title": "Archive News &amp; Video for Wednesday, 10 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-intervacc-progress-in-development/brief-intervacc-progress-in-development-of-new-vaccine-against-staphylococcus-aureus-infections-idUSFWN1P503A", "country": "US", "domain_rank": 408, "title": "BRIEF-Intervacc: Progress In Development Of New Vaccine Against Staphylococcus Aureus Infections", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.6, "site_type": "news", "published": "2018-01-10T15:41:00.000+02:00", "replies_count": 0, "uuid": "dbed060f4b8ba451279ce5e28669f4ec816ee853"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-intervacc-progress-in-development/brief-intervacc-progress-in-development-of-new-vaccine-against-staphylococcus-aureus-infections-idUSFWN1P503A", "ord_in_thread": 0, "title": "BRIEF-Intervacc: Progress In Development Of New Vaccine Against Staphylococcus Aureus Infections", "locations": [], "entities": {"persons": [{"name": "intervacc", "sentiment": "negative"}], "locations": [{"name": "sweden", "sentiment": "none"}, {"name": "us", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 10 (Reuters) - INTERVACC AB:\n* SIGNIFICANT PROGRESS HAS BEEN MADE IN THE DEVELOPMENT OF A NEW VACCINE AGAINST STAPHYLOCOCCUS AUREUS INFECTIONS\n* ‍COSTS RELATED TO MASTITIS ARE ESTIMATED ANNUALLY ABOUT 200 MSEK ONLY IN SWEDEN AND IN US ABOUT 4500 MSEK​\n* SAYS ‍NEED FOR A VACCINE TO COMPLEMENT OTHER PREVENTIVE MEASURES IS VERY LARGE​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\nOur Standards: The Thomson Reuters Trust Principles.", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-10T15:41:00.000+02:00", "crawled": "2018-01-11T12:43:22.011+02:00", "highlightTitle": ""}